Board Appointment

Stem Cell Sciences plc
27 July 2006



27.7.06                                                        Immediate Release

                       (Stem Cell Sciences plc. AIM: STEM)

                        NON-EXECUTIVE DIRECTOR APPOINTMENT

Stem Cell Sciences plc (AIM:STEM) is pleased to announce that
Jeremy Paul Scudamore, aged 59, has been appointed to the Stem Cell Sciences
Board of Directors as Non-executive Director with immediate effect.

Jeremy Scudamore was educated at Nottingham University. He joined I.C.I. as an
Economist and worked for the I.C.I. Group and later Zeneca in a number of
international commercial and strategic management roles. He has considerable
experience of Business in the Americas, Europe, Africa the Middle East and Asia.
He became Business Director for Zeneca Agrochemicals, Managing Director of
Zeneca Seeds and Plant science and then Chief Executive Officer of Zeneca
Specialties. In 1998/9 he led the £1.3bn buyout of Zeneca Specialties from
AstraZeneca to form the Avecia Group. At the time, this was the largest ever
buyout in Europe.  He was appointed CEO and later Chairman of the Avecia Group.
Having restructured and successfully divested all but the Biotechnology
businesses, he retired in 2006.

Jeremy has been Chair of the UK Chemicals Innovation team for the DTI, was on
the Boards of the Chemical Industry Association, Chemical and Engineering News
(Washington USA), European Chemical News, and was Chairman of Cyprotex plc.

Jeremy is currently a Non -executive Director of ARM Holdings plc and Chair of
the North West Science Council.

Peter Mountford, CEO of Stem Cell Sciences commented; "Jeremy has extensive
expertise in growing global businesses and maximising shareholder value.  He is
a valuable addition to our Board.  We are thrilled to have him on the team and
look forward to working with him."

Current Appointments Held:

Company Name                               Position   Appointed
ARM HOLDINGS PLC                           Director   26/04/2004

Past Appointments Held:

Company Name                               Position   Appointed    Resigned
ADVANTA RESEARCH LIMITED                   Director   06/02/1995   15/05/1998
ADVANTA TECHNOLOGY LIMITED                 Director   01/12/1995   15/05/1998
AVECIA BIOTECH PROPERTIES LIMITED          Director   30/03/2005   04/10/2005
AVECIA FINE CHEMICALS LIMITED              Director   18/02/2005   16/09/2005
AVECIA FINANCE PLC                         Director   23/06/1999   22/03/2006
AVECIA GROUP PLC                           Director   23/06/1999   22/03/2006
AVECIA HOLDINGS PLC                        Director   23/06/1999   22/03/2006
AVECIA 10 LIMITED                          Director   23/06/1999   17/03/2006
AVECIA CORPORATION LIMITED                 Director   23/06/1999   22/03/2006
AVECIA LIMITED                             Director   23/06/1999   22/03/2006
AVECIA PHARMACEUTICALS LIMITED             Director   21/02/2005   02/12/2005
AVECIA INKJET LIMITED                      Director   18/02/2005   17/02/2006
AVECIA INVESTMENTS LIMITED                 Director   13/07/1999   22/03/2006
AVECIA TRADING LIMITED                     Director   23/06/1999   31/07/2003
AVECIA TONER RESINS LIMITED                Director   23/06/1999   04/10/2005
AVECIA UK HOLDINGS LIMITED                 Director   23/06/1999   22/03/2006
AV NO. 2 LIMITED                           Director   22/01/2002   22/03/2006
AV NO.3 LIMITED                            Director   23/06/1999   19/04/2004
CHEMICAL INDUSTRIES ASSOCIATION LIMITED    Director   20/05/2000   03/01/2006
CYPROTEX SERVICES LIMITED                  Director   04/12/2001   17/02/2003
ICI(NOMINEE HOLDINGS) LIMITED              Director   06/09/1992   04/01/1994
ILIAD 3 LIMITED                            Director   23/06/1999   30/03/2004
ZENECA INTERNATIONAL LIMITED               Director   15/09/1993   01/07/1997

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc
Peter Mountford, Chief Executive Officer                           0131 662 9829

Weber Shandwick Square Mile                                        020 7067 0700
James Chandler/James White

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company
providing products in the burgeoning stem cell research and drug discovery
markets, in addition to the targeted development of cell-based therapies for
neurodegenerative disease and injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics.

SCS principal focus is in neurological disease. Revenues in the neurotech
market, including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to
US$110 billion*.

SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(TM)provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, a division of
Serologicals Inc.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchene's Muscular Dystrophy in 2006.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
             QDBEBBV